ストックスクリーナーアプリを入手
3.16
0.32%
0.01
アフターアワーズ：
3.15
-0.01
-0.32%
Esperion Therapeutics Inc (ESPR) 最新ニュース
Esperion Therapeutics, Inc. (ESPR) Latest Stock News & Headlines - Yahoo Finance
ESPR Stock Falls After Esperion’s Mixed Q4 — Retail Remains Unfazed, Eyes ‘Massive’ Upcoming Catalysts - Stocktwits
ESPR Stock Price, Quote & Chart - ChartMill
Esperion Therapeutics Company Profile & Introduction - Moomoo
Esperion Gains German Approval for ArchiMed Acquisition Deal - TipRanks
German antitrust clears Esperion (ESPR) merger with ArchiMed affiliate Essence Parent - Stock Titan
Glazer Capital (ESPR) reports 20,975,620 shares, an 8.15% position - Stock Titan
New peer-reviewed paper by more than 20 protein experts calls for rethinking dietary protein guidance beyond "eat more protein": National Pork Board reports - EurekAlert!
Esperion Therapeutics (NASDAQ: ESPR) to be acquired for $3.16/share plus CVRs - Stock Titan
Esperion Therapeutics(ESPR) Stock Options Chain | Quotes & News - Moomoo
ESPR Stock Chart | ESPERION THERAPEUTICS INC (NASDAQ:ESPR) - ChartMill
Esperion Therapeutics, Inc. 8-K Filing Details for May 28, 2026: Company Information, NASDAQ Listing, and Stock Option Plan Amendments - Minichart
Esperion (NASDAQ: ESPR) director receives 79,873-share stock award grant - Stock Titan
Esperion Therapeutics (ESPR) director receives 79,873-share stock award - Stock Titan
Esperion (NASDAQ: ESPR) director receives 79,873-share stock grant - Stock Titan
Director at Esperion (NASDAQ: ESPR) receives 79,873-share stock grant - Stock Titan
Director at Esperion Therapeutics (ESPR) receives 79,873-share equity award - Stock Titan
Esperion (NASDAQ: ESPR) investors approve 7M-share plan boost and board slate - Stock Titan
Esperion Therapeutics (ESPR) agrees to $3.16/share cash deal plus milestone CVRs - Stock Titan
ESPR News | ESPERION THERAPEUTICS INC (NASDAQ:ESPR) - ChartMill
Esperion Presents New Data from CLEAR Outcomes and the - GlobeNewswire
Trial tests cholesterol drug in kids with inherited high cholesterol - Stock Titan
Esperion Therapeutics stock (US2964331002): buyout by Archimed and fresh earnings put focus on futur - AD HOC NEWS
Epilogue On Esperion Therapeutics Stock (NASDAQ:ESPR) - Seeking Alpha
ETFs Investing in Esperion Therapeutics, Inc. Stocks - TradingView
Esperion Therapeutics (ESPR) price target decreased by 59.91% to 2.97 - MSN
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Sahm
Esperion Therapeutics estimates U.S. heart failure costs at 46B dollars a year, urges therapy optimization - Traders Union
Esperion Therapeutics stock (US2964331002): Archimed acquisition deal closes chapter on independent - AD HOC NEWS
ESPR Stock Surges 44% in a Month: Here's What You Need to Know - sharewise.com
Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026 - The Manila Times
Esperion Announces Two New Analyses Supporting Bempedoic - GlobeNewswire
Needham Maintains Esperion Therapeutics(ESPR.US) With Hold Rating - Moomoo
TradingKey - TradingKey
Esperion Therapeutics’ 10-Q Forward-Looking Statements Highlight Significant Uncertainty and Investor Risk - The Globe and Mail
Esperion Therapeutics (ESPR) Q4 Profit Swing Challenges Bearish Earnings Narratives - Sahm
Esperion Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Esperion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Buyout values Esperion (NASDAQ: ESPR) at $3.16 in cash plus CVR - Stock Titan
Hypercholesterolemia Treatment Market is expected to Hit US$ - openPR.com
Esperion Therapeutics Q1 2026 earnings preview - MSN
United StatesGoodwin Advises Esperion On $1.1 Billion Acquisition By ARCHIMED - Mondaq
Halper Sadeh LLC is Investigating Whether SILA, ESPR, CRBG, EQH are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
MSN Money - MSN
SHAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--ESPR, SILA, CRBG, and EQH - Sahm
BIOG's investee Esperion bought by ArchiMed for USD1 billion - marketscreener.com
Esperion (ESPR) was downgraded to a Hold Rating at Needham - The Globe and Mail
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Na - ChartMill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Nasdaq - GlobeNewswire Inc.
Needham downgrades Esperion Therapeutics (ESPR) - MSN
BioPharma Credit to Finance Archimed's Purchase of Biotech Growth Trust's Esperion Therapeutics - Moomoo
Esperion to be acquired by ARCHIMED - The Pharma Letter
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
2.11%
大文字化:
|
ボリューム (24 時間):